This is a routine procedural ruling with no material financial impact. The underlying patent litigation over Eylea/Pavblu continues — monitor for claim construction rulings, summary judgment motions, or trial dates that could affect Amgen's biosimilar launch timeline.
Price Chart
Executive Summary
Amgen's motion to remand two aflibercept (Eylea) patent infringement cases from the West Virginia MDL back to the Central District of California was denied. The court found no good cause for remand, citing its familiarity with the patents and the efficiency of keeping the case in the MDL despite the settlement of other co-defendants. This is a procedural loss for Amgen, keeping the litigation in a forum where the court has already issued substantive orders, but no damages or injunction were awarded and the underlying patent case continues unchanged.
Court Ruling Details
Key Facts
- Amgen's motion for suggestion of remand of two aflibercept patent cases from the MDL to the Central District of California was DENIED.
- The court found no good cause for remand, citing its familiarity with the case and the efficiency of continued MDL proceedings.
- All other actions in the MDL have been settled, leaving only the two Amgen cases.
- The underlying patent infringement claims regarding Regeneron's Eylea (aflibercept) and Amgen's Pavblu remain pending.
- No damages, injunction, or financial exposure was determined by this ruling.
Financial Impact
No financial impact from this procedural ruling; the underlying patent case continues without any damages awarded or injunction issued.
Risk Factors
- Adverse patent ruling could block or delay Amgen's Pavblu (aflibercept biosimilar) launch, impacting future revenue.
- Continued litigation creates legal expense and uncertainty, but no near-term financial exposure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2ac00a9fd8-AMGN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | ANALYST-DOWNGRADE | $382.47 $379.78 | ▲ +0.70% | ▲ +0.20% | $403.04 (−5.38%) |
Sep 8, 2026 24d ago | ANALYST-DOWNGRADE | $393.17 $375.65 | ▲ +4.46% | ▲ +3.34% | $403.04 (−2.51%) |
Aug 14, 2026 7w ago | Court Ruling | $415.21 $439.33 | ▲ +5.81% | ▲ +7.18% | $403.04 (−2.93%) |
Aug 13, 2026 7w ago | Insider Cluster | $415.21 $439.33 | ▲ +5.81% | ▲ +7.18% | $403.04 (−2.93%) |
Aug 11, 2026 7w ago | Court Ruling | $414.30 $425.28 | ▲ +2.65% | ▲ +3.05% | $403.04 (−2.72%) |
Aug 7, 2026 7w ago | Insider Cluster | $417.20 $419.38 | ▲ +0.52% | ▲ +0.57% | $403.04 (−3.39%) |
Aug 7, 2026 7w ago | Insider Cluster | $417.20 $419.38 | ▲ +0.52% | ▲ +0.57% | $403.04 (−3.39%) |
Aug 7, 2026 7w ago | Insider Cluster | $417.20 $419.38 | ▲ +0.52% | ▲ +0.57% | $403.04 (−3.39%) |
Aug 4, 2026 8w ago | GOVT-CONTRACT | $390.02 $414.30 | ▲ +6.23% | ▲ +6.33% | $403.04 (+3.34%) |
Jul 31, 2026 9w ago | 8-K | $378.87 $417.20 | ▼ −10.12% | ▼ −8.09% | $403.04 (−6.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access